Trial Profile
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Acronyms RECITE
- Sponsors Amgen
- 06 Feb 2024 According to Amgen media release, Data readout is anticipated in H2 2024.
- 01 Feb 2024 Planned End Date changed from 23 Mar 2025 to 24 Jan 2025.
- 21 Dec 2023 This trial has been completed in France, according to European Clinical Trials Database record.